Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Shuaishuai Xing und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Aldo-Keto Reductase Family 1 Member C3. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Government of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aldo-keto reductase 1C3 (AKR1C3) plays a key role in tumor progression and chemotherapy resistance, particularly in sorafenib-resistant hepatocellular carcinoma (HCC). Targeting AKR1C3 represents a promising strategy to restore chemosensitivity in resistant HCC. Previous research identified the lead compound S07-2005 through a cascade virtual screening approach (AKR1C3 IC50 = 130 ± 30 nM, SI (selective index) > 77). Using cocrystal-guided drug design, 30 was optimized to adopt an "L"-shaped conformation targeting AKR1C3's subpocket 1 (SP1) and oxyanion site (OS), enhancing inhibitory potency and selectivity (AKR1C3 IC50 = 5 ± 1 nM, SI > 2000). It enhanced sorafenib-induced ROS generation, promoted apoptosis, and restored sorafenib sensitivity in HCC models. In combination with sorafenib, compound 30 restored sorafenib sensitivity in HCC both in vitro and in vivo. Additionally, compound 30 demonstrated a favorable safety profile and pharmacokinetic properties, suggesting its potential as an adjunct to overcome AKR1C3-mediated chemotherapy resistance in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
- School of Chemistry and Materials Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Sub-lane Xiangshan, Hangzhou 310024, People's Republic of China.
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People's Republic of China.
- Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang 550004, People's Republic of China.
- Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, People's Republic of China.
- Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, Jiangsu, People's Republic of China.
ORCID-Profile: Siyu He, Qinglong Guo, Li Zhao, Pengfei Fang, Haopeng Sun
Förderung
- Natural Science Foundation of Jiangsu Province
- Government of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Xing, S., Jiang, J., Chu, X., Wang, X., Wang, Z., Li, X., Lv, B., Guo, C., He, S., Wang, L., Zhang, C., Guo, Q., Zhao, L., Fang, P., Feng, F., & Sun, H. (2025). Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03035
Vancouver
Xing S, Jiang J, Chu X, Wang X, Wang Z, Li X, et al. Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03035
BibTeX
@article{Xing2025,
author = {Xing, Shuaishuai and Jiang, Jiheng and Chu, Xianglin and Wang, Xiaolong and Wang, Zhiqiang and Li, Xinyu and Lv, Bingbing and Guo, Can and He, Siyu and Wang, Leyan and Zhang, Chenyu and Guo, Qinglong and Zhao, Li and Fang, Pengfei and Feng, Feng and Sun, Haopeng},
title = {Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03035}
}
EUVIMED